Company: CL
Filing Date: 2025-11-05
Form Type: 424B2
Source: 0001104659-25-106990
Chunk: 52

Company: COLGATE PALMOLIVE CO
Filing Date: 2025-11-05
Form: 424B2
Chunk 52
---
300 Park Avenue, New York, New York 10022-7499, Telephone: (212) 310-2000, E-mail:
Investor_Relations@colpal.com.

<div align='center'>S-24

Legal Matters</div>

The validity of the Notes will be passed upon for
Colgate by Hogan Lovells US LLP, Washington, D.C. Willkie Farr & Gallagher LLP, Chicago, Illinois has acted as counsel for
the underwriters.

<div align='center'>Experts</div>

The financial statements and management’s
assessment of the effectiveness of internal control over financial reporting (which is included in Management’s Annual Report on
Internal Control Over Financial Reporting) incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2024 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered
public accounting firm, given on the authority of said firm as experts in auditing and accounting.

<div align='center'>S-25</div>

PROSPECTUS

Debt Securities

| · | By                                                                   
 this prospectus, we may offer from time to time our debt securities. |

| · | When                                                                                                
 we offer debt securities, we will provide you with a prospectus supplement describing the           
 terms of the specific issue of debt securities including the offering price of the debt securities. 
 This prospectus may not be used to sell debt securities unless accompanied by the applicable        
 prospectus supplement.                                                                              |

| · | We                                                                                               
 may sell the debt securities on a continuous or delayed basis to the public through underwriters 
 acting individually or through a group of underwriters which may be managed or co-managed        
 by one or more underwriters designated by us, through agents or dealers, directly to one         
 or more other purchasers or by any combination of these methods of sale. We reserve the sole     
 right to accept, and together with any agents, dealers and underwriters, reserve the right       
 to reject, in whole or in part, any proposed purchase of debt securities. For additional         
 information on the method of sale, refer to the section entitled “Plan of Distribution”          
 below.                                                                                           |

| · | The                                                                                        
 name or names of any agents or underwriters involved in the sale of any debt securities,   
 the proceeds to us from the offering, any discounts and commissions to be allowed or paid  
 to the agents or underwriters, all other items constituting underwriting